Protection against doxorubicin cardiomyopathy in rats: Role of phosphodiesterase inhibitors type 4

Pharmacology, Toxicology and Pharmaceutical Science

• Doxorubicin 100%
• Phosphodiesterase IV Inhibitor 100%
• Cardiomyopathy 100%
• Tumor Necrosis 50%
• Cardiotoxicity 16%
• Rolipram 16%
• Reactive Oxygen Metabolite 16%
• Cytokine 16%
• Heart Disease 16%
• Tumor Necrosis Factor Inhibitor 16%
• Antioxidant 16%
• Lactate Dehydrogenase 16%
• Congestive Heart Failure 16%
• Creatine Kinase 16%
• Intraperitoneal Injection 16%

Biochemistry, Genetics and Molecular Biology

• Doxorubicin 100%
• Phosphodiesterase 100%
• Oxidative Stress 16%
• Mitochondrion 16%
• Cytokine 16%
• Blood Level 16%
• Cell Damage 16%
• Lactate Dehydrogenase 16%
• Heterochromatin 16%
• Creatine Kinase 16%
• TNF Inhibitor 16%

Medicine and Dentistry

• Rolipram 16%
• Heterochromatin 16%